Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meleah Hilton

Physician Assistant Shelby, NC Physician Assistant

NPI 1760787618 CMS profile 10606349

113 E Grover St, Shelby, NC 28150

Open in the dashboard

General payments

$4,800

295 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meleah Hilton of Shelby, NC is reported in the CMS Open Payments database as having received $4,800 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29 2
2023 General $483 16
2022 General $2,172 136
2021 General $2,117 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meleah Hilton
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Meleah Hilton were reported at $29. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Meleah Hilton Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,117 $132 $37–$438 $132
2022 $2,172 $155 $48–$522 $149
2023 $483 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $29 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $872 70 payments
  2. Novo Nordisk Inc $372 27 payments
  3. GlaxoSmithKline, LLC. $362 7 payments
  4. Novartis Pharmaceuticals Corporation $359 19 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $351 23 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $317 19 payments
  7. AstraZeneca Pharmaceuticals LP $288 19 payments
  8. Amarin Pharma Inc. $282 14 payments
  9. Sanofi-Aventis U.S. LLC $263 14 payments
  10. Lilly USA, LLC $259 18 payments
  11. Other $1,075 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,800 295 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $458 29 payments
  2. XIFAXAN $317 19 payments
  3. VRAYLAR $288 28 payments
  4. Vascepa $282 14 payments
  5. ENTRESTO $270 14 payments
  6. Ozempic $246 18 payments
  7. RYBELSUS $246 18 payments
  8. LINZESS $206 10 payments
  9. UBRELVY $192 20 payments
  10. SOLIQUA 100/33 $190 10 payments
  11. Other $3,008 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 172 drugs

Part D claims

9,868

Median for Physician Assistant: 241

Drug cost

$1,515,519

Median for Physician Assistant: $4,110

Branded share of claims

22.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 12 $574,070
Ozempic Semaglutide Brand 89 $117,709
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 75 $74,946
Mounjaro Tirzepatide Brand 58 $71,470
Farxiga Dapagliflozin Propanediol Brand 67 $67,575
Jardiance Empagliflozin Brand 35 $55,403
Linzess Linaclotide Brand 46 $50,282
Eliquis Apixaban Brand 66 $49,920
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 35 $44,332
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 57 $41,392

The 10 drugs with the highest cost, of 172 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$35,486

Of which drugs: $371

Medicare patients

160

Average age 71

Services billed

923

100 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 42%
Diabetes 31%
Depression 31%
Chronic kidney disease 21%
COPD 17%
Ischemic heart disease 15%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record